HealthEquityの空売り状況は、投資家がHealthEquityの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

HealthEquity (NASDAQ:HQY) 株価情報, 空売り情報

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BIDU

CWCO

GETY

SAIC

STNE

CNNマネーの『恐怖＆貪欲指数』 は市場全体のセンチメントに若干の改善が見られたことを示したが、月曜日と同じく『極度の恐怖』圏のままである。

経済データの好調から株価がプラス350ポイント上昇：投資家の恐れが和らぐも、Greed指数は「極度の恐怖」ゾーンのまま

HealthEquity Inc

HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter financial results after the market close on Tuesday and shares are sinking. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results">of the report</a>.
<ul>
<li>Q4 Revenue: $311.82 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $306.05 million</li>
</ul>
<ul>
<li>Q4 Adjusted EPS: 69 cents, versus estimates of 72 cents</li>
</ul>
Total revenue was up 19% on a year-over-year basis. The company reported 9.9 million health savings accounts (HSAs) as of Jan. 31, up 14% year-over-year. Total accounts came in at 17 million as of Jan. 31. Total HSA assets were up 27% year-over-year to $32.1 billion.
HealthEquity said it repurchased 1.4 million shares of its common stock in fiscal 2025 for $122.2 million. The company had $177.8 million remaining under its buyback as of Jan. 31.
&#8220;Team Purple finished fiscal ‘25 in strong fashion, with record revenues and major strides in advancing our strategic initiatives, allowing us to provide our&nbsp;outlook&nbsp;for an even stronger fiscal ‘26,&#8221; said Scott Cutler, president and CEO of HealthEquity. 
&#8220;With a focus on Member First Secure Mobile Experiences, we are executing against our 3Ds strategy to Deepen partnerships, Deliver remarkable experiences, and Drive member outcomes for our Clients, Network Partners, and members.&#8221;
Outlook: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion versus estimates of $1.301 billion. The company anticipates full-year earnings of $3.57 to $3.74 per share versus estimates of $3.71 per share.
The guidance came in below estimates at the midpoint, which appears to be weighing on shares after hours.
HealthEquity executives will further discuss the quarter on a call with investors and analysts at 4:30 p.m. ET.
HQY Price Action: <a href="http://benzinga.com/quote/hqy">HealthEquity shares</a> were down 12.46% after hours, trading at $89 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44385576/five-below-q4-earnings-preview-analyst-less-optimistic-due-to-macro-tariffs-and-short-holiday-season">Five Below Q4 Earnings Preview: Analyst Less Optimistic Due To Macro, Tariffs And Short Holiday Season</a></li>
</ul>
Photo: Shutterstock.

Guidance

Health Care

Analyst Ratings

Movers

Insurance

HealthEquity Stock Falls After Reporting Q4 Results: Revenue Beat, EPS Miss, Soft Guidance

<h3>Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares moved upwards by 28.9% to $0.17 during Tuesday's after-market session. The company's market cap stands at $3.0 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares increased by 19.99% to $4.56. The market value of their outstanding shares is at $209.9 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 14.88% to $1.09. The company's market cap stands at $16.7 million. </li>
<li>Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) shares moved upwards by 12.02% to $8.29. The company's market cap stands at $30.2 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares increased by 8.46% to $3.46. The market value of their outstanding shares is at $418.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock increased by 6.91% to $1.7. The company's market cap stands at $14.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock fell 12.3% to $89.15 during Tuesday's after-market session. The market value of their outstanding shares is at $7.7 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 10.57% to $28.26. The company's market cap stands at $367.7 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) stock declined by 9.6% to $0.7. The market value of their outstanding shares is at $29.0 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock declined by 7.26% to $11.5. The company's market cap stands at $34.9 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock declined by 7.1% to $2.88. The company's market cap stands at $330.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 6.63% to $2.62. The market value of their outstanding shares is at $449.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ADGM

CRGX

OABI

PULM

RLYB

SCNX

SVRA

VRPX

XCUR

12 Health Care Stocks Moving In Tuesday's After-Market Session

WIIM

HealthEquity shares are trading lower after the company reported worse-than-expected Q4 Adj. EPS results.

Earnings Beats

CORRECTION: HealthEquity Q4 2025 Adj. EPS $0.69 Misses $0.72 Estimate, Sales $311.817M Beats $306.053M Estimate

HealthEquity Sees FY26 $3.57-$3.74 Vs $3.71 Est.; Revenue $1.280B-$1.305B Vs $1.301B Est.

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.
On Monday, stocks continued their recovery from last week&#8217;s sell-off, which had pushed the S&amp;P 500 into correction territory amid growing concerns over the U.S. economy&#8217;s ability to withstand President Donald Trump&#8216;s trade war.
The two-day meeting of the Federal Open Market Committee will begin today as they discuss and announce their decision on interest rates slated to be released tomorrow. Chairman Jerome Powell will address a press conference on Wednesday afternoon.
The 10-year Treasury yield stood at 4.31%, while the two-year yield was at 4.04%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 99% chance that the Federal Reserve will keep interest rates unchanged tomorrow.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.21%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.22%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped slightly in premarket on Monday. The SPY was down 0.15% to $566.37, and the QQQ also declined 0.25% to $481.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, energy, and consumer staples stocks led Monday&#8217;s market rally, with significant gains across the S&amp;P 500. Conversely, consumer discretionary stocks dipped.
This sector-driven strength propelled the Dow Jones higher extending the market&#8217;s recovery after last week&#8217;s sharp declines, which saw the Dow lose 3.1% and the S&amp;P 500 drop over 2%.
In company news, Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares surged 30% on acquisition interest, and Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares climbed 9% following the launch of new AI models.
Economic data presented a mixed picture, with retail sales growth below expectations, a sharp drop in the NY Empire State Manufacturing Index, and a decline in housing market confidence.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.31%</td>
<td>17,808.66</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.64%</td>
<td>5,675.12</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.85%</td>
<td>41,841.63</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.19%</td>
<td>2,068.33</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The market sentiment seemed to be recovering on Monday after the S&amp;P 500 index recorded an upmove in 90% of its issues for two consecutive days. Ryan Detrick of Carson Research highlighted that this was a rare occurrence when 90% of S&amp;P 500 constituents rose back-to-back for two days.
According to the historical data shared by him, this has only happened 12 times since 1972 and the index has been higher in all instances after a year.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Back-to-back 90% advancing issues for the S&amp;P 500. Using <a href="https://twitter.com/NDR_Research?ref_src=twsrc%5Etfw">@NDR_Research</a> data back to 1972 shows higher six and 12 months later every single time, with much better than average returns. I&#39;m sure this will make everyone mad, but it made me &#x1f603; <a href="https://t.co/QWf8lJx2eQ">pic.twitter.com/QWf8lJx2eQ</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1901824344839336317?ref_src=twsrc%5Etfw">March 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Liz Ann Sonders and Kevin Gordon of Charles Schwab said in a note "The only thing we can be certain of is that things will remain uncertain for the time being."
They quoted the data from a few years ago when confidence metrics went through a soft patch giving a &#8220;false&#8221; recessionary signal amid strong underlying growth and the hard data. They termed it as a &#8220;vibecession.&#8221;
Whereas they termed the current period as &#8220;vibespansion," which was evident a few months ago, however, many strong sentiment metrics are receding. "If the soft data stay soft long enough, we see more risk of the hard data catching down," the note added.
Edward Yardeni or Yardeni Research highlighted that the markets could have bottomed out on Thursday last week and rose on Friday and Monday because there was no comment from Trump on tariffs.
He said, "From a sentiment perspective, it is possible that Thursday's selloff followed by Friday's rally marked a bottom in the correction. We will be more inclined to call a bottom when we see the stock market move higher on a day or days when Trump blusters about tariffs again, which he did not do on Friday."
"Any day without a Trump tariff comment is a good day for the market. We know that on April 2 there will be lots of reciprocal tariffs imposed on many more nations by the administration, undoubtedly eliciting lots of comments from Tariff Man," he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>February&#8217;s housing starts, building permits, and import price index data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, February&#8217;s industrial production and capacity utilization data will be released at 9:15 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) was up 0.77% in premarket on Tuesday ahead of its earnings before the opening bell. Analysts expect earnings of 4 cents per share on revenue of $424.00 million.</li>
</ul>
<ul>
<li>HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) advanced 0.28% as Wall Street expects it to report earnings of 72 cents per share on revenue of $306.05 million after the closing bell.</li>
</ul>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STN#NASDAQ">STN</a>) rose 0.49% ahead of its earnings after the closing bell. Analysts expect earnings of 35 cents per share on revenue of $647.56 million.</li>
</ul>
<ul>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) jumped 2.33% after posting an upbeat earnings result for its fourth quarter on Monday.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 6.83% after reporting worse-than-expected fourth-quarter financial results.</li>
</ul>
<ul>
<li>Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) was 4.39% higher continuing the momentum from yesterday following the launch of new AI models.</li>
</ul>
<ul>
<li>Bon Natural Life Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) surged 29.71% after it secured $12 million in gross proceeds from a best efforts unit offering.</li>
</ul>
<ul>
<li>Harrow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) zoomed 24.14% after it projected 2025 revenue of over $280 million, driven by branded products.</li>
</ul>
<ul>
<li>Bakkt Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) plunged 30.24% after it rescheduled its fourth-quarter earnings call to March 18, 2025.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.35% to hover around $68.28 per barrel.
The gold spot index was up by 0.70% to $3,022.11 per ounce. Its last record high was at $3,028.49 per ounce. The Dollar Index was down by 0.05% at the 103.322 level.
Asian markets closed higher on Tuesday with China&#8217;s CSI 300, Japan's Nikkei 225, South Korea's Kospi, Australia's ASX 200, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex advancing in trade. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44371661/ai-bubble-bursting-magnificent-7s-profit-margins-face-pressure-as-capital-spending-can-tumble-in">AI Bubble Bursting? Magnificent 7&#8217;s Profit Margins Face Pressure As &#8216;Capital Spending Can Tumble&#8217; In 2025</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Futures

Economics

Federal Reserve

Bakkt Holdings, Inc. Class A Common Stock

BKKT

HROW

SGMO

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

ATER

BEKE

BETR

CTRN

ESLT

ETON

FLOC

HUYA

INKT

OCFT

ORLA

SNDL

SRFM

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) will release its fourth-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/hqy/earnings">Tuesday, March 18.</a>
Analysts expect the Draper, Utah-based company to report quarterly earnings at 72 cents per share, up from 63 cents per share in the year-ago period. HealthEquity projects quarterly revenue of $305.82 million, compared to $262.39 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 9, 2024, HealthEquity posted mixed results for the third quarter.
HealthEquity shares gained 3.4% to close at $100.72 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barrington Research analyst Alexander Paris maintained an Outperform rating and a price target of $112 on March 14, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Raymond James analyst C. Gregory Peters maintained an Outperform rating and raised the price target from $105 to $120 on Feb. 25, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Mizuho analyst Steven Valiquette initiated coverage on the stock with an Outperform rating and a price target of $126 on Dec. 4, 2024. This analyst has an accuracy rate of 60%.</li>
<li>B of A Securities analyst Allen Lutz maintained a Buy rating and raised the price target from $100 to $120 on Nov. 13, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Deutsche Bank analyst George Hill maintained a Buy rating and increased the price target from $102 to $103 on Sept. 4, 2024. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png" alt="" class="wp-image-828822" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035721/image-141.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Long Ideas

HealthEquity Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index surging more than 350 points during the session. All three of the major indices recorded back-to-back gains.
Despite gains recorded on Monday, US stocks recorded losses last week. The Dow dipped around 3.1% to record its worst week since March 2023. The S&amp;P 500 dipped more than 2%, recording its fourth straight losing week.
Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) shares jumped 30% on Monday after the company announced it received a non-binding proposal from WHP Global to acquire the company for $13 per share in cash. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) shares gained 9% after the company announced the launch of ERNIE 4.5 and deep-thinking model ERNIE X1.
On the economic data front, U.S. retail sales rose 0.2% month-over-month in February following a revised 1.2% decline in January but down from market expectations of a 0.6% rise. The NY Empire State Manufacturing Index declined 26 points to -20.0 in March, recording the lowest reading since May 2023. The NAHB/Wells Fargo Housing Market Index fell to 39 in March versus a reading of 42 in February.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, energy, and consumer staples stocks recording the biggest gains on Monday. However, consumer discretionary stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 353 points to 41,841.63 on Monday. The S&amp;P 500 rose 0.64% to 5,675.12, while the Nasdaq Composite climbed 0.31% at 17,808.66 during Monday's session.
Investors are awaiting earnings results from IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) , and StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 22.1, the index remained in the &#8220;Extreme Fear&#8221; zone on Monday, versus a prior reading of 20.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Jumps 350 Points Following Positive Economic Data: Investor Fear Eases, But Greed Index Remains In 'Extreme Fear' Zone

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects IHS Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) to report quarterly earnings at 4 cents per share on revenue of $424.00 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. IHS shares gained 0.5% to $3.93 in after-hours trading.</li>
<li>Analysts are expecting HealthEquity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) to post quarterly earnings at 72 cents per share on revenue of $306.05 million. The company will release earnings after the markets close. HealthEquity shares rose 1.1% to $101.87 in after-hours trading.</li>
<li>Getty Images Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) posted upbeat results for its fourth quarter on Monday. Getty Images shares fell 0.9% to $2.1301 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported worse-than-expected fourth-quarter financial results. Sangamo Therapeutics shares fell 3% to $0.98 in the after-hours trading session.</li>
<li>Analysts expect StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) to post quarterly earnings at 35 cents per share on revenue of $647.56 million after the closing bell. StoneCo shares rose 0.1% to $10.20 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo courtesy: Shutterstock

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday

U.S. stocks settled higher on Friday, with the S&amp;P 500 surging more than 2% during the session.
Despite Friday's gains, stocks recorded losses last week. The Dow dipped around 3.1% to record its worst week since March 2023. The S&amp;P 500 dipped more than 2%, recording its fourth straight losing week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: Citizens Capital Markets</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Market Perform rating on Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) on March 14.</li>
<li>Recent News: On March 15, Rocket Lab USA announced its third Pioneer spacecraft for Varda Space Industries, Inc. is successfully operating on orbit.</li>
</ul>
Analyst: Mark Hughes
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 83%</li>
<li>Latest Rating: Maintained a Hold rating on James River Group Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) and cut the price target from $6 to $5 on March 11. This analyst sees around 25% surge in the stock.</li>
<li>Recent News: On March 4, James River Group reported worse-than-expected fourth-quarter EPS results.</li>
</ul>
Analyst: Rob Owens 
<ul>
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 82%</li>
<li>Latest Rating: Maintained an Overweight rating on SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) and cut the price target from $32 to $28 on March 13. This analyst sees around 52% upside in the stock.</li>
<li>Recent News: On March 12, SentinelOne reported fourth-quarter revenue of $225.5 million, beating the consensus estimate of $222.25 million, according to Benzinga Pro.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 82%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and cut the price target from $140 to $130 on March 13. This analyst sees around 29% upside in the stock.</li>
<li>Recent News: On March 5, Micron named Mark Liu and Christie Simons to Board of Directors.</li>
</ul>
Analyst: Alexander Paris
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 81%</li>
<li>Latest Rating: Maintained an Outperform rating on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a price target of $112 on March 14. This analyst sees around 15% upside in the stock.</li>
<li>Recent News: On Feb. 18, HealthEquity affirmed guidance for fiscal 2025 and 2026.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>

Price Target

JRVR

RKLB

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 4.96% on an annualized basis producing an average annual return of 15.86%. Currently, HealthEquity has a market capitalization of $8.93 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $446.23 today based on a price of $102.99 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741122914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In HealthEquity 10 Years Ago Would Be Worth Today

Wells Fargo analyst Stan Berenshteyn maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Overweight and raises the price target from $110 to $125.

Wells Fargo Maintains Overweight on HealthEquity, Raises Price Target to $125

Across the recent three months, 5 analysts have shared their insights on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $115.6, with a high estimate of $126.00 and a low estimate of $105.00. This current average reflects an increase of 11.42% from the previous average price target of $103.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1740513670_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of HealthEquity's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>About HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.55% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): HealthEquity's ROE excels beyond industry benchmarks, reaching 0.27%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): HealthEquity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About HealthEquity Stock

Raymond James analyst C. Gregory Peters maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $105 to $120.

Raymond James Maintains Outperform on HealthEquity, Raises Price Target to $120

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 7.61% on an annualized basis producing an average annual return of 18.76%. Currently, HealthEquity has a market capitalization of $9.80 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $572.84 today based on a price of $113.12 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740081609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning HealthEquity Stock In The Last 10 Years

The total number of HSAs as of January&nbsp;31, 2025 was 9.9 million, an increase of 14%, from 8.7 million as of January&nbsp;31, 2024.&nbsp;
The Company closed its fiscal year 2025 with 17.0 million Total Accounts, an increase of 9%, from 15.7 million as of January&nbsp;31, 2024.&nbsp;
HSA Assets grew to $32.1 billion as of January&nbsp;31, 2025, an increase of 27% from $25.2 billion a year earlier.
 &nbsp;

HealthEquity Affirms Guidance For Fiscal 2025 And 2026

AVGO

EPAM

Live On CNBC, Karen Firestone Announces Bought More EPAM Systems; Bought More Broadcom; Bought More Chemed; Announces Trimmed HealthEquity Position; Trimmed Westinghouse Air Brake Technologies Position

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 7.6% on an annualized basis producing an average annual return of 18.74%. Currently, HealthEquity has a market capitalization of $9.72 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $557.13 today based on a price of $112.15 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739223931_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Press Releases

HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results

HealthEquity Caps 2024 With Widespread Recognition For Its Workplace Excellence

HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

Tech-Powered Innovation Transforms Member Experiences and Earns HealthEquity Industry Recognition

General

HealthEquity Reports Year-End Sales Metrics

The Path Forward: How Commuting Impacts the Return to Office Experience

Forbes and U.S. News & World Report Agree: HealthEquity is One of America's Best Places to Work

HealthEquity Community Foundation Announces First Grant Recipients and Opens Next Funding Cycle

HealthEquity Assist™: A new suite of integrated benefit solutions that drive deeper engagement, deliver cost savings, and increase transparency for employee benefits

HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2025 Financial Results

Comments

HealthEquity

空売り

HealthEquity (NASDAQ:HQY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル